A considerable proportion of patients namely around 30% according recently published data [64] and baseline characteristics from clinical trials in 1st line treatment of ALK-positive NSCLC patients [86, 87, 27] already has a diagnosis of brain metastases before the start of ALK-inhibitor therapy. The gene discussed is ALK; the disease is non-small cell lung carcinoma.